Insider Trading Alert - BIIB, FDS And GCO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 23, 2014, 58 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $300.00 to $14,156,086.00.

Highlighted Stocks Traded by Insiders:

Biogen Idec (BIIB) - FREE Research Report

Posner Brian S, who is Director at Biogen Idec, sold 605 shares at $315.00 on June 23, 2014. Following this transaction, the Director owned 6,000 shares meaning that the stake was reduced by 9.16% with the 605-share transaction.

The shares most recently traded at $316.45, up $1.45, or 0.46% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 484
  • 12-Week # shares sold: 10,172
  • 24-Week # shares sold: 83,049

The average volume for Biogen Idec has been 1.5 million shares per day over the past 30 days. Biogen Idec has a market cap of $75.8 billion and is part of the health care sector and drugs industry. Shares are up 12.12% year-to-date as of the close of trading on Monday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 39.8. Currently, there are 13 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

FactSet Research Systems (FDS) - FREE Research Report

Laird Joseph E Jr, who is Director at FactSet Research Systems, sold 1,000 shares at $116.49 on June 23, 2014. Following this transaction, the Director owned 2,500 shares meaning that the stake was reduced by 28.57% with the 1,000-share transaction.

The shares most recently traded at $117.19, up $0.70, or 0.6% since the insider transaction. Historical insider transactions for FactSet Research Systems go as follows:

  • 4-Week # shares sold: 17,371
  • 12-Week # shares sold: 17,371
  • 24-Week # shares sold: 136,871

The average volume for FactSet Research Systems has been 306,200 shares per day over the past 30 days. FactSet Research Systems has a market cap of $4.9 billion and is part of the technology sector and computer software & services industry. Shares are up 8.68% year-to-date as of the close of trading on Monday.

FactSet Research Systems Inc. provides integrated financial information and analytical applications to investment community in the United States, Europe, and the Asia Pacific. The stock currently has a dividend yield of 1.34%. The company has a P/E ratio of 24.4. Currently, there are 2 analysts who rate FactSet Research Systems a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FDS - FREE

TheStreet Quant Ratings rates FactSet Research Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full FactSet Research Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Genesco (GCO) - FREE Research Report

Dickens Marty G, who is Director at Genesco, sold 2,000 shares at $80.49 on June 23, 2014. Following this transaction, the Director owned 10,734 shares meaning that the stake was reduced by 15.71% with the 2,000-share transaction.

The shares most recently traded at $81.27, up $0.78, or 0.96% since the insider transaction. Historical insider transactions for Genesco go as follows:

  • 4-Week # shares sold: 9,785
  • 12-Week # shares sold: 30,033
  • 24-Week # shares sold: 79,967

The average volume for Genesco has been 152,100 shares per day over the past 30 days. Genesco has a market cap of $1.9 billion and is part of the services sector and retail industry. Shares are up 10.61% year-to-date as of the close of trading on Monday.

Genesco Inc. is engaged in the retail and wholesale of footwear, apparel, and accessories. The company operates in five segments: Journeys Group, Schuh Group, Lids Sports Group, Johnston & Murphy Group, and Licensed Brands. The company has a P/E ratio of 20.6. Currently, there are 3 analysts who rate Genesco a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GCO - FREE

TheStreet Quant Ratings rates Genesco as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Genesco Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball